Lunar mining and Moon land claims fall into a gray area of international law, but negotiations are underway to avoid conflict and damage to spacecraft
The UK is about to have its first space launch – but Cornwall is unlikely to become a new Cape Canaveral
Nobel-winning quantum weirdness undergirds an emerging high-tech industry, promising better ways of encrypting communications and imaging your body
It was the first time scientists confirmed that nitrous oxide increases if nitrogenous fertilizers are used excessively for rice farming.
The new products emit 95 percent less harmful substances than a normal cigarette because they heat tobacco instead of burning it.
CJ CheilJedang exporting its plant-based PlanTable brand to 30 countries after selling 3 million products shortly after launch
S. Korea’s Celltrion Partners with US firm Abpro for breast cancer treatment
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.